Nebie I, Diarra A, Ouedraogo A, Tiono A B, Konate A T, Gansane A, Soulama I, Cousens S, Leroy O, Sirima S B
Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso, West Africa.
Parasite Immunol. 2009 Aug;31(8):474-80. doi: 10.1111/j.1365-3024.2009.01130.x.
We performed a single-blind, randomized phase 1 trial of the long synthetic peptide (LSP) of merozoite surface protein-3 (MSP3) in adults living in Burkina Faso. Thirty eligible volunteers were randomized to receive either the MSP3-LSP candidate vaccine or tetanus toxoid vaccine as a control. A dose of each vaccine was administered on days 0, 28 and 112 and the vaccine was formulated with aluminium hydroxide. Humoral immune responses were assessed by ELISA at days 0, 28, 56, 112, 140, 252 and 365 and cell-mediated immune responses by lymphoproliferation assay and by ELISA on days 0, 56 and 140. IgG responses to four peptides of MSP3 were similar in both vaccine groups. Higher IgG concentrations were recorded after the beginning of malaria high transmission season in both vaccine groups. The lymphocyte proliferation and the production of IFN-gamma in response to stimulation with the four overlapping peptides increased following vaccination in the MSP3-LSP vaccine group, but did not change appreciably in the control group. In contrast to natural infection, MSP3-LSP did not boost humoral responses to the four overlapping peptides of MSP3 to any detectable degree in our semi-immune adult. MSP3-LSP may be more immunogenic in young children with little or no acquired immunity.
我们在布基纳法索的成年人中进行了一项关于裂殖子表面蛋白-3（MSP3）长合成肽（LSP）的单盲、随机1期试验。30名符合条件的志愿者被随机分配接受MSP3-LSP候选疫苗或破伤风类毒素疫苗作为对照。每种疫苗在第0、28和112天各接种一剂，疫苗用氢氧化铝配制。在第0、28、56、112、140、252和365天通过ELISA评估体液免疫反应，在第0、56和140天通过淋巴细胞增殖试验和ELISA评估细胞介导的免疫反应。两个疫苗组对MSP3四种肽的IgG反应相似。在疟疾高传播季节开始后，两个疫苗组的IgG浓度均有所升高。在MSP3-LSP疫苗组中，接种疫苗后，对四种重叠肽刺激的淋巴细胞增殖和IFN-γ产生增加，但在对照组中没有明显变化。与自然感染不同，在我们的半免疫成年人中，MSP3-LSP并没有将对MSP3四种重叠肽的体液反应提高到任何可检测的程度。MSP3-LSP在几乎没有或没有获得性免疫的幼儿中可能具有更强的免疫原性。
